KR102606799B1 - 폴리-adp 리보스 폴리머라제 (parp) 억제제 - Google Patents

폴리-adp 리보스 폴리머라제 (parp) 억제제 Download PDF

Info

Publication number
KR102606799B1
KR102606799B1 KR1020197021891A KR20197021891A KR102606799B1 KR 102606799 B1 KR102606799 B1 KR 102606799B1 KR 1020197021891 A KR1020197021891 A KR 1020197021891A KR 20197021891 A KR20197021891 A KR 20197021891A KR 102606799 B1 KR102606799 B1 KR 102606799B1
Authority
KR
South Korea
Prior art keywords
mmol
alkyl
disease
optionally substituted
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197021891A
Other languages
English (en)
Korean (ko)
Other versions
KR20190098760A (ko
Inventor
다이스케 다카하시
아서 클루지
바라트 라구
난 지
Original Assignee
미토브리지, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미토브리지, 인크. filed Critical 미토브리지, 인크.
Publication of KR20190098760A publication Critical patent/KR20190098760A/ko
Application granted granted Critical
Publication of KR102606799B1 publication Critical patent/KR102606799B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197021891A 2016-12-30 2017-12-28 폴리-adp 리보스 폴리머라제 (parp) 억제제 Active KR102606799B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440581P 2016-12-30 2016-12-30
US62/440,581 2016-12-30
PCT/US2017/068636 WO2018125961A1 (en) 2016-12-30 2017-12-28 Poly-adp ribose polymerase (parp) inhibitors

Publications (2)

Publication Number Publication Date
KR20190098760A KR20190098760A (ko) 2019-08-22
KR102606799B1 true KR102606799B1 (ko) 2023-11-28

Family

ID=61007849

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021891A Active KR102606799B1 (ko) 2016-12-30 2017-12-28 폴리-adp 리보스 폴리머라제 (parp) 억제제

Country Status (33)

Country Link
US (2) US11034670B2 (https=)
EP (1) EP3562822B1 (https=)
JP (1) JP7141399B2 (https=)
KR (1) KR102606799B1 (https=)
CN (1) CN110167926B (https=)
AR (1) AR110706A1 (https=)
AU (1) AU2017388376B2 (https=)
CA (1) CA3047137A1 (https=)
CO (1) CO2019007906A2 (https=)
CY (1) CY1124565T1 (https=)
DK (1) DK3562822T3 (https=)
EA (1) EA201991412A1 (https=)
ES (1) ES2875841T3 (https=)
HR (1) HRP20210887T1 (https=)
HU (1) HUE054382T2 (https=)
IL (1) IL267676B (https=)
JO (1) JOP20190115B1 (https=)
LT (1) LT3562822T (https=)
MA (1) MA47165B1 (https=)
MD (1) MD3562822T2 (https=)
MX (1) MX393606B (https=)
MY (1) MY199045A (https=)
PH (1) PH12019501529A1 (https=)
PL (1) PL3562822T3 (https=)
PT (1) PT3562822T (https=)
RS (1) RS61895B1 (https=)
SA (1) SA519401894B1 (https=)
SI (1) SI3562822T1 (https=)
SM (1) SMT202100321T1 (https=)
TW (1) TWI773718B (https=)
UA (1) UA124777C2 (https=)
WO (1) WO2018125961A1 (https=)
ZA (2) ZA201904004B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037371B1 (ru) * 2015-10-07 2021-03-19 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения
SMT202100321T1 (it) * 2016-12-30 2021-07-12 Mitobridge Inc Inibitori della poli-adp ribosio polimerasi (parp)
US12459899B2 (en) 2019-10-30 2025-11-04 DIGMBIO, Inc. Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient
EP4328224A4 (en) * 2021-04-22 2025-06-18 Wigen Biomedicine Technology (Shanghai) Co., Ltd. PARP INHIBITOR WITH PIPERAZINE STRUCTURE, MANUFACTURING METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
WO2023002011A1 (en) * 2021-07-23 2023-01-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Gram-negative bacteria efflux pump inhibitors
CN113603630B (zh) * 2021-08-10 2023-06-27 苏州小栗医药科技有限公司 一种4-苯基哌啶盐酸盐的合成方法
AU2023346584A1 (en) 2022-09-19 2025-03-27 Basf Se Azole pesticidal compounds
JPWO2024101336A1 (https=) 2022-11-07 2024-05-16
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
CN120917007A (zh) * 2023-05-19 2025-11-07 上海海和药物研究开发股份有限公司 一种芳基脲类parp1抑制剂、其制备方法及用途
CN117024357B (zh) * 2023-07-03 2026-02-24 山东第二医科大学 一种针对brca突变的选择性抑制剂及其用途
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN117510404A (zh) * 2023-11-29 2024-02-06 山西永津集团有限公司 一种4-氨基烟酸的制备方法
WO2025111705A1 (en) * 2023-11-30 2025-06-05 Waverley Pharma Inc. Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
CN118084678B (zh) * 2024-03-01 2024-09-06 长沙唯楚医药科技有限公司 一种2-溴-6-氟苯胺的制备方法
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025227032A1 (en) * 2024-04-26 2025-10-30 Remix Therapeutics Inc. Methods for degradation of cyclin k and inhibition of cyclin dependent kinases
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070737A2 (en) 2000-03-20 2001-09-27 Sepracor, Inc. Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
ATE402704T1 (de) 2000-03-27 2008-08-15 Abbott Gmbh & Co Kg Dopamin-d3-rezeptor-liganden zur behandlung von sucht
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CA2557541C (en) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
ATE540936T1 (de) * 2004-06-30 2012-01-15 Janssen Pharmaceutica Nv Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
JP2009501235A (ja) 2005-07-15 2009-01-15 シェーリング コーポレイション 癌処置において有用なキナゾリン誘導体
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP2697206B1 (en) 2011-04-10 2019-04-03 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
PL3027598T3 (pl) 2013-07-31 2017-09-29 Merck Patent Gmbh Pochodne oksochinazolinylo-butanoamidowe
WO2015169421A1 (en) 2014-05-07 2015-11-12 Merck Patent Gmbh Heterocyclyl-butanamide derivatives
CN105924434A (zh) * 2015-02-28 2016-09-07 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
SMT202100321T1 (it) * 2016-12-30 2021-07-12 Mitobridge Inc Inibitori della poli-adp ribosio polimerasi (parp)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof

Also Published As

Publication number Publication date
HRP20210887T1 (hr) 2021-07-23
BR112019011676A2 (pt) 2019-10-15
JP2020512298A (ja) 2020-04-23
PL3562822T3 (pl) 2021-09-13
CA3047137A1 (en) 2018-07-05
EP3562822B1 (en) 2021-03-10
AR110706A1 (es) 2019-04-24
JOP20190115A1 (ar) 2019-05-20
MA47165B1 (fr) 2021-06-30
AU2017388376A1 (en) 2019-07-04
EA201991412A1 (ru) 2019-11-29
MY199045A (en) 2023-10-11
CN110167926B (zh) 2022-09-13
RS61895B1 (sr) 2021-06-30
MX393606B (es) 2025-03-19
PH12019501529A1 (en) 2020-09-14
TW201834657A (zh) 2018-10-01
MX2019007870A (es) 2019-08-16
AU2017388376B2 (en) 2022-01-06
EP3562822A1 (en) 2019-11-06
IL267676B (en) 2021-09-30
SMT202100321T1 (it) 2021-07-12
TWI773718B (zh) 2022-08-11
ES2875841T3 (es) 2021-11-11
DK3562822T3 (en) 2021-05-03
PT3562822T (pt) 2021-06-02
US11034670B2 (en) 2021-06-15
ZA201904004B (en) 2022-12-21
US20220033380A1 (en) 2022-02-03
CY1124565T1 (el) 2022-07-22
US11993585B2 (en) 2024-05-28
SI3562822T1 (sl) 2021-08-31
JOP20190115B1 (ar) 2023-09-17
IL267676A (en) 2019-08-29
US20200071299A1 (en) 2020-03-05
UA124777C2 (uk) 2021-11-17
WO2018125961A8 (en) 2019-05-23
WO2018125961A1 (en) 2018-07-05
HUE054382T2 (hu) 2021-09-28
MD3562822T2 (ro) 2021-07-31
MA47165A (fr) 2019-11-06
NZ754385A (en) 2024-07-05
CO2019007906A2 (es) 2019-10-21
SA519401894B1 (ar) 2023-02-19
KR20190098760A (ko) 2019-08-22
JP7141399B2 (ja) 2022-09-22
ZA202003310B (en) 2021-08-25
CN110167926A (zh) 2019-08-23
LT3562822T (lt) 2021-06-10

Similar Documents

Publication Publication Date Title
KR102606799B1 (ko) 폴리-adp 리보스 폴리머라제 (parp) 억제제
EP4406948A1 (en) Pyridine derivative and use thereof
EP3423451B1 (en) Inhibitors of wdr5 protein-protein binding
RU2717238C2 (ru) Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
JP6949952B2 (ja) スピロ環化合物
BR112018003812B1 (pt) Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit
BR112016011024B1 (pt) Composto, composição farmacêutica, e, usos dos mesmos
BR112020005934A2 (pt) inibidor de pde9 e uso do mesmo
KR20150135794A (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도
CN103443107B (zh) 噻唑并嘧啶化合物
BR112019011676B1 (pt) Composição farmacêutica e composto inibidor de poli-adp ribose polimerase (parp), bem como seus usos
HK40013326A (en) Poly-adp ribose polymerase (parp) inhibitors
HK40013326B (en) Poly-adp ribose polymerase (parp) inhibitors
EA040674B1 (ru) Ингибиторы поли(адф-рибоза)полимеразы (parp)
HK40043421A (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
HK1192227B (en) Thiazolopyrimidine compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190725

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220915

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230320

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230823

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231122

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231123

End annual number: 3

Start annual number: 1

PG1601 Publication of registration